Guiding cancer therapy.

Around 90% of drugs that look promising in in vivo trials end up failing in clinical settings; 0.02% of all drugs developed eventually end up on the market. At PharmaLegacy, we understand these numbers are intimidating. We aim at mitigating all risks your pipelines have, and improving these numbers. With our ex-vivo tumor study models, notably our tumor histopathology studies, 3D tumor tissue cultures and tumor microenvironment studies, we at PharmaLegacy are confident that we can take your pipelines from start to finish.

Put your trust in the right CRO. Put your trust in PharmaLegacy.

Contact Us
Ex-Vivo Tumor Studies


The myriad of interactions between the immune system and cancer have been critical to drug discovery. However, data derived from current in vivo and in vitro cancer models using standardized cell lines and animal models often fails to accurately reflect the true tumor environment. This often makes it difficult to study a drug’s actual effect, resulting in inaccurate studies, extended timelines, and wasted resources.

PharmaLegacy has developed an ex vivo assays platform utilizing 3D culture prepared from fresh, mice-derived tumors, complete with an intact tumor immune microenvironment. Through the correlation of the ex vivo tumor drug response with the characteristics of the tumor microenvironment, we identify and validate biomarkers of drug sensitivity and resistance.

The use of fresh, mice-derived tissue samples is only the beginning. PharmaLegacy utilizes cutting-edge technologies in next-generation RNA sequencing, flow cytometry, multiplex cytokine assays, mass spectrometry, immunohistochemistry and many more to help our research partners take their most promising therapies from preclinical data to clinical results.

Why do we need tumor tissue culture?

· The interactions between the tumor immune microenvironment and cancer cells are key to drug discovery.

· Current cell lines and in vivo models most often fail to accurately reflect the true tumor environment.

· Studies utilizing cell lines or in vivo models generally fail to predict a drug’s actual effect.

What is so good about mice-derived, 3D tumor culture?

· Phenotypically-accurate intact tumor tissues retain tumor-immune microenvironment.

· The effects of test compound on biomarker release, changes in immune microenvironment, or inflammatory process can be evaluated.

Pharmalegacy’s Tissue Culture Platform

· Tissue slices can be kept in culture for up to 7 days.

· Multiple slices can be created from a single tumor.

· Customized protocols and study design to meet your needs.

Readouts of Tumor Tissue Culture Platform

To achieve excellence in tumor imaging, PharmaLegacy uses the IVIS Lumina XRMS Series III, Perkin Elmer’s latest two-dimensional, multi-mode living imaging system with the highest sensitivity for bioluminescence, multi-spectral fluorescence, radioisotope and X-ray imaging. Compared with the previous generation of similar products, the new system greatly enhanced the fluorescence imaging ability through advanced spectral separation technology. Updates to the X-ray imaging hardware have enabled the X-ray imaging of rats in addition to X-ray imaging of mice.

Best-In-Class Bioluminescence, Multispectral Fluorescence and Integrated X Optical Imaging Technology

The IVIS Lumina XRMS III integrates several years of advanced optical imaging technology to create an easy-to-operate, multi-mode in vivo optical imaging system with remarkable performance. Researchers can combine high-sensitivity bioluminescence, multispectral fluorescence, radionuclide and low-dose X-ray imaging in mice, rats and other model animals. With up to 26 filters, users can image dozens of fluorescent probes ranging from green to near infrared light.

Flexible Conversion of X Imaging in Mice or Rats

Lumina XRMS was used to perform X-ray imaging on mice, rats, and other animal models weighing 500-600 grams. Lumina XRMS is the only imaging system on the market that can overlay and fuse optical and X-ray signals in all imaging fields.

Case Study:

Hematoma and In Vivo Imaging of Nalm-6

Committed to quality:

  • Completed over 400 FDA / CFDA IND filings
  • AAALAC accredited vivarium
  • 24/7 access to PharmaLegacy representatives
  • 380,000 square feet of facility space

Looking for a CRO that can deliver pipeline breakthroughs? Contact PharmaLegacy.

Contact Us

Providing Better Data for Critical Immuno-Oncology Pipeline Decisions

PharmaLegacy works to get you the answers you need with our wide selection of carefully developed in vivo and in vitro models. In this document, you’ll see a sample of the in vitro assays we run along with a sample of real-world data from them. See why over 700 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical pipeline decisions.


    We’re ready when you are.

    Tell us your pharmacology challenges.